Partnering Spotlight
Seegene: Multiplex assays key to companion diagnostics
The quality of medical treatment is dependent on rapid and accurate diagnosing of the disease, as well as safeguarding the life of the patient. Apart from infectious diseases, most diseases do not have that “tell-all” diagnostic marker that provides an adequate picture of the patient and their particular disease. Seegene, Inc., sees a combination of surrogate markers in a single clinically validated assay as the most effective tool in disease identification, treatment and management, while keeping the patient in focus. Read more »
partneringNEWS:TV
The excitement of the industry insiders is unfortunately not matched by those funding and regulating it. The challenges facing the industry are increasing every day. Read more »
Valuable lessons are learned when experienced business development executives draw from their dealmaking experience and dive into some of the common and not so common pitfalls in partnering. Read more »
A few nimble VCs and entrepreneurs are developing funds and corporate structures that may once again make private biotech companies attractive investments. Companies changing the game have one common theme: they focus on the drug, not the company. Read more »
There is a rising interest in assets in some of the most sought-after therapeutic areas: those where access is all but assured, patients are more easily identified, and the commercial call-point is narrow. Read more »
Biotech/pharma licensing deals face many challenges, not the least of which is the possibility of deal termination due to lack of efficacy, safety or due diligence concerns; many deals come to an end for reasons that are completely outside the control of the biotech partner. Read more »
Nycomed fielded several offers before Takeda landed the prize that resulted in one of 2011′s most significant deals. In this exclusive, Anton Gueth of Gueth Consulting interviews two of the deal’s prime movers, Catherine Sazdanoff of Takeda and Gunnar Gardemyr of Nycomed, to learn how and why this big deal came together. Read more »
Say hello to Walmart, Nintendo and Nestle, just a few of the new players creating unexpected opportunities in business development that recognize “the patient is the new key opinion leader.” Read more »
Executives moved seamlessly and rapidly from real-world partnering meetings to connecting with the wider online community that opened with the launch of partnering360 during BIO-Europe 2011. Read more »
Hot Companies
Newsletter